Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol

M. Kavallaris, C. A. Burkhart, Susan Band Horwitz

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

A major impediment to the successful use of Taxol in the treatment of cancer is the development of drug resistance. The major cellular target of Taxol is the microtubule that is comprised of α- and β-tubulin heterodimers. Binding sites for Taxol have been delineated on the β-tubulin subunit that has six isotypes. We have recently described increased expression of the brain-specific human class III β-tubulin isotype, encoded by the Hβ4 gene, in both Taxol-resistant ovarian tumours and non-small-cell lung cancer cell lines. To evaluate directly the role of the class III β-tubulin isotype in mediating Taxol resistance, antisense phosphorothioate oligodeoxynucleotides (ODN) targeted against various regions of the Hβ4 gene have been designed and examined for their efficacy in reducing Hβ4 gene and protein expression. Taxol-resistant lung cancer cells, A549-T24, which are 17-fold resistant to Taxol and display a fourfold increase in Hβ4 expression compared to the parental A549 cells, were treated with 1 μM antisense ODNs. Two ODNs, AS1 and AS3, were found to reduce mRNA expression by 40-50%, as determined by reverse transcription polymerase chain reaction. A concentration-dependent reduction in Hβ4 mRNA expression was demonstrated with AS1 ODN. Immunofluorescence staining of cells treated with AS1 ODN revealed a decrease in class III protein expression which corresponded to a 39% increase in sensitivity to Taxol (P < 0.005). These findings support an important role for Hβ4 (class III) β-tubulin expression in Taxol resistance and have potential implications for the treatment of Taxol-resistant tumours.

Original languageEnglish (US)
Pages (from-to)1020-1025
Number of pages6
JournalBritish Journal of Cancer
Volume80
Issue number7
DOIs
StatePublished - 1999

Fingerprint

Antisense Oligonucleotides
Tubulin
Paclitaxel
Pharmaceutical Preparations
Oligodeoxyribonucleotides
Neoplasms
Messenger RNA
Drug Resistance
Non-Small Cell Lung Carcinoma
Microtubules
Genes
Reverse Transcription
Fluorescent Antibody Technique
Lung Neoplasms
Proteins
Binding Sites
Staining and Labeling
Gene Expression
Cell Line
Polymerase Chain Reaction

Keywords

  • Antisense
  • Drug resistance
  • Lung cancer
  • Taxol
  • Tubulin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. / Kavallaris, M.; Burkhart, C. A.; Band Horwitz, Susan.

In: British Journal of Cancer, Vol. 80, No. 7, 1999, p. 1020-1025.

Research output: Contribution to journalArticle

@article{b7f54f1771af47c7858e58b51ed9abc8,
title = "Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol",
abstract = "A major impediment to the successful use of Taxol in the treatment of cancer is the development of drug resistance. The major cellular target of Taxol is the microtubule that is comprised of α- and β-tubulin heterodimers. Binding sites for Taxol have been delineated on the β-tubulin subunit that has six isotypes. We have recently described increased expression of the brain-specific human class III β-tubulin isotype, encoded by the Hβ4 gene, in both Taxol-resistant ovarian tumours and non-small-cell lung cancer cell lines. To evaluate directly the role of the class III β-tubulin isotype in mediating Taxol resistance, antisense phosphorothioate oligodeoxynucleotides (ODN) targeted against various regions of the Hβ4 gene have been designed and examined for their efficacy in reducing Hβ4 gene and protein expression. Taxol-resistant lung cancer cells, A549-T24, which are 17-fold resistant to Taxol and display a fourfold increase in Hβ4 expression compared to the parental A549 cells, were treated with 1 μM antisense ODNs. Two ODNs, AS1 and AS3, were found to reduce mRNA expression by 40-50{\%}, as determined by reverse transcription polymerase chain reaction. A concentration-dependent reduction in Hβ4 mRNA expression was demonstrated with AS1 ODN. Immunofluorescence staining of cells treated with AS1 ODN revealed a decrease in class III protein expression which corresponded to a 39{\%} increase in sensitivity to Taxol (P < 0.005). These findings support an important role for Hβ4 (class III) β-tubulin expression in Taxol resistance and have potential implications for the treatment of Taxol-resistant tumours.",
keywords = "Antisense, Drug resistance, Lung cancer, Taxol, Tubulin",
author = "M. Kavallaris and Burkhart, {C. A.} and {Band Horwitz}, Susan",
year = "1999",
doi = "10.1038/sj.bjc.6690507",
language = "English (US)",
volume = "80",
pages = "1020--1025",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol

AU - Kavallaris, M.

AU - Burkhart, C. A.

AU - Band Horwitz, Susan

PY - 1999

Y1 - 1999

N2 - A major impediment to the successful use of Taxol in the treatment of cancer is the development of drug resistance. The major cellular target of Taxol is the microtubule that is comprised of α- and β-tubulin heterodimers. Binding sites for Taxol have been delineated on the β-tubulin subunit that has six isotypes. We have recently described increased expression of the brain-specific human class III β-tubulin isotype, encoded by the Hβ4 gene, in both Taxol-resistant ovarian tumours and non-small-cell lung cancer cell lines. To evaluate directly the role of the class III β-tubulin isotype in mediating Taxol resistance, antisense phosphorothioate oligodeoxynucleotides (ODN) targeted against various regions of the Hβ4 gene have been designed and examined for their efficacy in reducing Hβ4 gene and protein expression. Taxol-resistant lung cancer cells, A549-T24, which are 17-fold resistant to Taxol and display a fourfold increase in Hβ4 expression compared to the parental A549 cells, were treated with 1 μM antisense ODNs. Two ODNs, AS1 and AS3, were found to reduce mRNA expression by 40-50%, as determined by reverse transcription polymerase chain reaction. A concentration-dependent reduction in Hβ4 mRNA expression was demonstrated with AS1 ODN. Immunofluorescence staining of cells treated with AS1 ODN revealed a decrease in class III protein expression which corresponded to a 39% increase in sensitivity to Taxol (P < 0.005). These findings support an important role for Hβ4 (class III) β-tubulin expression in Taxol resistance and have potential implications for the treatment of Taxol-resistant tumours.

AB - A major impediment to the successful use of Taxol in the treatment of cancer is the development of drug resistance. The major cellular target of Taxol is the microtubule that is comprised of α- and β-tubulin heterodimers. Binding sites for Taxol have been delineated on the β-tubulin subunit that has six isotypes. We have recently described increased expression of the brain-specific human class III β-tubulin isotype, encoded by the Hβ4 gene, in both Taxol-resistant ovarian tumours and non-small-cell lung cancer cell lines. To evaluate directly the role of the class III β-tubulin isotype in mediating Taxol resistance, antisense phosphorothioate oligodeoxynucleotides (ODN) targeted against various regions of the Hβ4 gene have been designed and examined for their efficacy in reducing Hβ4 gene and protein expression. Taxol-resistant lung cancer cells, A549-T24, which are 17-fold resistant to Taxol and display a fourfold increase in Hβ4 expression compared to the parental A549 cells, were treated with 1 μM antisense ODNs. Two ODNs, AS1 and AS3, were found to reduce mRNA expression by 40-50%, as determined by reverse transcription polymerase chain reaction. A concentration-dependent reduction in Hβ4 mRNA expression was demonstrated with AS1 ODN. Immunofluorescence staining of cells treated with AS1 ODN revealed a decrease in class III protein expression which corresponded to a 39% increase in sensitivity to Taxol (P < 0.005). These findings support an important role for Hβ4 (class III) β-tubulin expression in Taxol resistance and have potential implications for the treatment of Taxol-resistant tumours.

KW - Antisense

KW - Drug resistance

KW - Lung cancer

KW - Taxol

KW - Tubulin

UR - http://www.scopus.com/inward/record.url?scp=0032904694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032904694&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6690507

DO - 10.1038/sj.bjc.6690507

M3 - Article

VL - 80

SP - 1020

EP - 1025

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -